What medications are best for high intraocular pressure?
Elevated intraocular pressure (IOP), or ocular hypertension, requires careful evaluation by an ophthalmologist before initiating any treatment. Medications are not prescribed based solely on elevated IOP—clinicians must first rule out glaucoma and assess risk factors such as optic nerve appearance, visual field integrity, corneal thickness (central corneal thickness), age, family history, and ethnicity. If treatment is indicated, first-line pharmacotherapy typically includes topical prostaglandin analogs—such as latanoprost, travoprost, or bimatoprost—which enhance uveoscleral outflow and generally provide the greatest IOP reduction with once-daily dosing and favorable safety profiles.
Other classes of topical agents may be used depending on individual patient factors: beta-blockers (e.g., timolol) reduce aqueous humor production but are contraindicated in patients with asthma, COPD, or bradycardia; alpha-2 agonists (e.g., brimonidine) also decrease aqueous production and may be useful in select cases, though they carry risks of allergic conjunctivitis and systemic sedation; carbonic anhydrase inhibitors (e.g., dorzolamide) inhibit aqueous formation and are often used as adjunctive therapy. Fixed-dose combination drops—like brimonidine/timolol or latanoprost/timolol—are frequently employed to improve adherence and efficacy when monotherapy is insufficient.
Oral carbonic anhydrase inhibitors (e.g., acetazolamide) are reserved for acute situations—such as angle-closure glaucoma attacks—or short-term use due to systemic side effects including metabolic acidosis, paresthesias, fatigue, and kidney stone risk. Importantly, no oral medications are approved or routinely recommended for chronic management of primary open-angle glaucoma or ocular hypertension. Lifestyle modifications—including regular aerobic exercise, avoiding prolonged head-down positions, and limiting excessive caffeine intake—may offer modest supportive benefits but should never replace evidence-based medical therapy.
Ultimately, treatment decisions must be individualized. Regular monitoring—including tonometry, optic disc assessment, retinal nerve fiber layer imaging (e.g., OCT), and perimetry—is essential to evaluate therapeutic response and disease progression. Never self-prescribe or adjust glaucoma medications without direct supervision from a qualified eye care professional.